What are the key synthesis steps for Delgocitinib?
The synthesis of Delgocitinib involves several key steps, often starting with the preparation of a pyrimidine intermediate. One described route begins with 4,6-dichloropyrimidine, which is reacted with 3-amino-1-(tetrahydro-2H-pyran-4-yl)propan-1-ol to form a substituted pyrimidine. This intermediate then undergoes further reactions, including potential cyclization and coupling steps, to build the core structure of Delgocitinib. A common approach involves introducing the pyrrolo[2,3-d]pyrimidine core, often through reactions with substituted pyrroles and subsequent functionalization. The final stages typically involve attaching the necessary side chains and functional groups to achieve the complete Delgocitinib molecule.
How do patents cover Delgocitinib's synthesis?
Patents related to Delgocitinib often claim not only the compound itself but also specific methods of its synthesis [1]. These method patents can cover novel intermediates, specific reaction conditions, or overall synthetic pathways designed to be more efficient, cost-effective, or to produce a purer product. Companies file these patents to protect their investment in developing and optimizing manufacturing processes. The patent landscape for Delgocitinib's synthesis can be complex, with potential for overlapping claims from different entities and ongoing legal challenges [2].
When do Delgocitinib's synthesis patents expire?
The expiration dates for patents covering Delgocitinib's synthesis vary depending on the specific patent and its filing date. These dates are crucial for determining when generic manufacturers might be able to produce and market their own versions of the drug. Information on patent expiration timelines for pharmaceutical compounds like Delgocitinib can be found through patent databases and specialized services that track pharmaceutical intellectual property [1][2].
What are the potential challenges to Delgocitinib synthesis patents?
Patents covering Delgocitinib's synthesis can be challenged on various grounds, including obviousness, lack of novelty, or insufficient description of the invention. Competitors, particularly generic drug manufacturers, may seek to invalidate these patents to clear the way for their own products. Litigation can arise over issues such as infringement or the validity of the patent claims. The outcome of these legal challenges can significantly impact the market exclusivity period for Delgocitinib [2].
Who makes Delgocitinib and its related intermediates?
Delgocitinib is developed and manufactured by pharmaceutical companies. For instance, Mitsubishi Tanabe Pharma Corporation is associated with the development of Delgocitinib. The synthesis process may involve several stages, and different companies might be involved in producing specific intermediates or carrying out particular steps of the manufacturing process.
What are the regulatory considerations for Delgocitinib synthesis?
The synthesis of Delgocitinib must adhere to strict regulatory guidelines set by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulations cover Good Manufacturing Practices (GMP), ensuring the quality, safety, and efficacy of the drug. Any changes to the synthesis process, intermediates, or manufacturing facilities require regulatory approval.
How does Delgocitinib's synthesis impact its cost?
The complexity and efficiency of the Delgocitinib synthesis process can directly influence its manufacturing cost. Novel or patented synthetic routes may initially be more expensive to implement due to specialized reagents or equipment. As patents expire and more efficient or generic manufacturing processes are developed, the cost of producing Delgocitinib may decrease.
Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com